Shenzhen-Hong Kong Cell Valley Obtains U.S. FDA Cosmetic Manufacturing Facility Registration
Recently, Shenzhen-Hong Kong Cell Valley successfully completed registration as a cosmetic product manufacturing facility under the Federal Food, Drug, and Cosmetic Act (FDCA), following approval by the U.S. Food and Drug Administration (FDA). The registration details have been officially published on the FDA website, marking a significant milestone in international regulatory compliance for this product line.
Following the U.S. FDA Drug Master File (DMF) filing for its exosome raw materials and prior approval by the International Nomenclature Cosmetic Ingredient (INCI) committee, Cell Valley Group has now secured FDA registration as a cosmetic manufacturing facility. These three major international certifications collectively validate that Cell Valley’s exosome products have met rigorous international standards in quality control, process stability, and safety assessment—aligning with both pharmaceutical and cosmetic regulatory requirements. This achievement lays a strong compliance foundation for clinical translation and global market expansion.
Looking ahead, Cell Valley Group will continue to accelerate the industrialization and internationalization of its exosome technologies, driving innovation in global healthcare and wellness.
